Epogin set for Japanese filing in chemotherapy setting
This article was originally published in Scrip
Chugai (Roche) will file for the approval of its mainstay product Epogin (epoetin beta) for the additional indication of chemotherapy-induced anaemia in Japan by the end of this year.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.